News | December 15, 2022
LG Chem inks deal with Innovent Biologics for gout treatment candidate
LG Chem will receive totaling up to $95.5 million for the China rights
LG Chem will receive totaling up to $95.5 million for the China rights
EC grants conditional marketing authorization based on the EFFISAYIL trial
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Subscribe To Our Newsletter & Stay Updated
